NeuroPace Inc
NPCENext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for NPCE. That does not mean none is planned.
Get an email about NPCE's next catalysts
Track NeuroPace (NPCE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
NPCE Earnings Report
EPS Est: $-0.14 | FQ end Sep/2026 | Call: amc
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cerebrolysin | Phase 3 | Stroke | - | - |
L-Alpha glycerylphosphorylcholine | Phase 3 | Stroke | - | - |
NaCl | Phase 2 | Cadasil | - | - |
Frequently asked questions
What is in NeuroPace Inc's drug pipeline?→
CatalystAlert tracks 3 drug candidates in NeuroPace Inc's (NPCE) pipeline across Phase 3, Phase 2. Its lead program is Cerebrolysin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NeuroPace Inc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for NeuroPace Inc (NPCE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NPCE biotech catalysts?→
Add NPCE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NeuroPace Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.